Spain modernises blood services and product controls:
This article was originally published in Clinica
Executive Summary
Spain has established a national blood services network and haemovigilance system, with which to implement new technical standards, in line with EU legislation. As well as seeking to ensure higher quality standards, the Decree, which transposes EU directives 2002/98/CE and 2004/33/CE, sets out new requirements for the storage, transport, distribution and traceability of blood and blood products. One of the EU-wide objectives of harmonising such standards is to enable member states to more easily exchange blood and blood products between them. The regulations also affect, however, all blood products entering the EU. The shortage of blood products in Ireland is deemed to be a major barrier to bioscientific R&D (see this issue, p 7).
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.